Current Opinion in Pediatrics,
Journal Year:
2024,
Volume and Issue:
unknown
Published: Nov. 21, 2024
Adoptive
immunotherapy
brings
hope
to
children
and
young
adults
diagnosed
with
high-risk
solid
tumors.
Cellular
(cell)
therapies
such
as
chimeric
antigen
receptor
(CAR)
T
cell,
CAR
natural
killer
(NK)
cell
(TCR)
therapy
are
potential
avenues
of
targeted
limited
long-term
toxicities.
However,
development
for
tumors
is
in
its
nascent
stages.
Here,
we
will
review
the
current
clinical
experience,
barriers
efficacy,
strategies
improve
response
patient
access.
bioRxiv (Cold Spring Harbor Laboratory),
Journal Year:
2024,
Volume and Issue:
unknown
Published: Dec. 9, 2024
Abstract
Background
Hepatocellular
carcinoma
represents
a
significant
global
health
challenge,
affecting
over
million
patients
annually,
arising
mainly
from
chronic
liver
diseases,
with
majority
being
related
to
viral
infections.
However,
despite
the
groundbreaking
clinical
results
of
immune
checkpoint
blockades
and
adoptive
cell
therapies,
we
still
face
non-responders
accompanied
by
high
rebound
rates
after
resection.
Considering
that
main
concern
is
overcome
highly
specialized
immunosuppressive
tumor
microenvironment
individual
patient,
characterization
particular
source
cells
used
in
ACT
immense
importance.
Approved
therapies
use
modified
peripheral
blood
individuals.
At
same
time,
tumor-infiltrating
lymphocytes
are
underrepresented
even
if
they
have
garnered
interest
due
their
potential
target
tumor-specific
antigens
more
effectively.
Methods
In
this
study,
employed
allogenic
autologous
sources
for
expansion
stimulation,
resulting
T-cell
transfer
experiments
determining
effector
differentiation
anti-tumor
effects
possible
implementation
re-stimulation.
Results
We
determined
success
rate
expanding
stimulating
consistent
CD8
fractions
HCC
patients.
To
showcase
effectiveness
stimulated
T-cells
different
sources,
generated
lines
derived
margin
center
an
HBV-induced
immune-suppressive
TME.
found
effective
responses
supported
death
induction,
ferroptosis,
proptosis
apoptosis
triggered
all
depending
on
area
cells.
Conclusion
Effector
present
viable
cell-based
therapy
combined
inhibitors
patients,
especially
resection,
suppress
strategies
parental
level.
Human Vaccines & Immunotherapeutics,
Journal Year:
2024,
Volume and Issue:
20(1)
Published: Aug. 5, 2024
Multiple
research
studies
have
demonstrated
the
efficacy
of
lactic
acid
bacteria
in
boosting
both
innate
and
adaptive
immune
responses.
We
created
a
Lactococcus
lactis
variant
that
produces
modified
combination
protein
with
Fms-like
tyrosine
kinase
3
ligand
co-stimulator
O
×
40
ligand,
known
as
HuFOLactis.
The
genetically
was
purposely
to
activate
T
cells,
NK
DC
cells
laboratory
setting.
Furthermore,
we
explored
possibility
using
tumor-penetrating
peptide
iRGD
deliver
HuFOLactis-activated
hard-to-reach
tumor
areas.
Following
brief
stimulation
HuFOLactis,
cell
phenotypes
functions
were
assessed
flow
cytometry.
Confocal
microscopy
employed
demonstrate
infiltrative
cytotoxic
capabilities
iRGD-modified
within
spheroids.
against
tumors
xenograft
mouse
models.
HuFOLactis
treatment
resulted
notable
activation,
by
elevated
levels
CD25,
CD69,
CD137.
Additionally,
these
activated
showed
heightened
cytokine
production
enhanced
cytotoxicity
MKN45
lines.
Incorporation
modification
facilitated
infiltration
into
multicellular
spheroids
(MCSs).
iRGD,
anti-PD-1
treatment,
effectively
halted
growth
prolonged
survival
model
gastric
cancer.
Current Opinion in Pediatrics,
Journal Year:
2024,
Volume and Issue:
unknown
Published: Nov. 21, 2024
Adoptive
immunotherapy
brings
hope
to
children
and
young
adults
diagnosed
with
high-risk
solid
tumors.
Cellular
(cell)
therapies
such
as
chimeric
antigen
receptor
(CAR)
T
cell,
CAR
natural
killer
(NK)
cell
(TCR)
therapy
are
potential
avenues
of
targeted
limited
long-term
toxicities.
However,
development
for
tumors
is
in
its
nascent
stages.
Here,
we
will
review
the
current
clinical
experience,
barriers
efficacy,
strategies
improve
response
patient
access.
